background
acut
stroke
patient
larg
arteri
occlus
diseas
laod
distinct
pathophysiolog
may
respond
diff
erent
anticoagul
treatment
compar
effi
caci
lowmolecularweight
heparin
lmwh
nadroparin
calcium
aspirin
asian
acut
stroke
patient
laod
method
acut
ischaem
stroke
patient
onset
symptom
less
h
laod
diagnos
transcrani
doppler
imag
carotid
duplex
scan
magnet
reson
angiographi
recruit
patient
randomli
assign
receiv
either
subcutan
nadroparin
calcium
antifactor
xa
ml
twice
daili
oral
aspirin
mg
daili
day
receiv
aspirin
mg
daili
month
studi
regist
wwwstrokecenterorgtri
number
rankin
scale
dichotomis
odd
ratio
ci
haemorrhag
transform
infarct
sever
advers
event
similar
group
posthoc
analys
patient
without
laod
treat
patient
show
similar
proport
good
outcom
aspirin
lmwh
group
vs
vs
respect
interpret
overal
result
support
signifi
cant
benefi
lmwh
aspirin
patient
laod
benefi
ts
indic
outcom
measur
warrant
investig
use
anticoagul
acut
stroke
patient
larg
arteri
atherosclerosi
particularli
intracrani
atherosclerosi
stroke
third
common
caus
death
worldwid
lead
caus
disabl
adult
burden
stroke
particularli
heavi
asia
account
half
worldwid
mortal
stroke
acut
intervent
ischaem
stroke
current
subject
intens
clinic
research
among
medic
treatment
aspirin
tissu
plasminogen
activ
shown
benefi
cial
eff
ect
outcom
howev
treatment
eff
ect
aspirin
small
use
tissu
plasminogen
activ
limit
narrow
therapeut
window
antithrombot
agent
use
acut
ischaem
stroke
inhibit
clot
propag
prevent
reembolis
facilit
clot
lysi
howev
randomis
control
trial
found
unfraction
heparin
eff
ectiv
improv
function
outcom
sever
mediums
randomis
placebocontrol
trial
use
lowmolecularweight
heparin
lmwh
heparinoid
treatment
acut
ischaem
stroke
report
sinc
fraxiparin
ischaem
stroke
fiss
studi
nadroparin
calcium
chines
patient
posit
primari
outcom
result
reproduc
larger
fissbi
studi
trial
org
acut
stroke
treatment
toast
tinzaparin
acut
ischem
stroke
trial
taist
studi
recent
systemat
review
metaanalys
lmwh
heparinoid
acut
ischaem
stroke
conclud
immedi
fulldos
anticoagul
therapi
associ
net
shortterm
longterm
benefi
routin
use
type
anticoagul
support
howev
debat
continu
asia
whether
result
fiss
studi
posit
trial
lmwh
due
chanc
relat
ethnic
diff
erenc
underli
pathophysiolog
mechan
ischaem
stroke
extracrani
atherosclerot
stenosi
wellknown
risk
factor
stroke
worldwid
contrast
intracrani
larg
arteri
occlus
diseas
laod
import
caus
stroke
among
asian
hispan
african
american
asian
data
suggest
laod
caus
ischaem
stroke
third
half
patient
predomin
intracrani
laod
asian
stroke
patient
might
explain
benefi
cial
eff
ect
lmwh
chines
patient
reproduc
studi
white
peopl
concord
hypothesi
posthoc
analysi
toast
studi
shown
heparinoid
treatment
could
increas
odd
favour
outcom
patient
stroke
secondari
laod
background
posit
trial
defi
nite
diff
erenc
stroke
subtyp
especi
intracrani
atherosclerosi
asian
uncertainti
remain
benefi
lmwh
laod
studi
object
test
hypothesi
subcutan
nadroparin
calcium
superior
aspirin
improv
stroke
outcom
month
patient
acut
ischaem
stroke
laod
studi
academ
fund
investigatoriniti
multicentr
randomis
control
trial
blind
outcom
assess
done
multipl
trial
site
hong
kong
singapor
april
sept
studi
protocol
receiv
ethic
committe
approv
particip
centr
particip
legal
accept
repres
provid
written
inform
consent
patient
diagnos
acut
ischaem
stroke
randomli
assign
receiv
either
nadroparin
calcium
antifactor
xa
ml
subcutan
twice
daili
lmwh
group
aspirin
mg
daili
aspirin
group
day
receiv
aspirin
mg
daili
month
inclus
criteria
follow
age
year
clinic
diagnosi
acut
ischaem
stroke
symptom
stroke
less
h
receiv
fi
rst
dose
trial
medic
count
time
last
known
symptom
free
presenc
motor
defi
cit
result
acut
stroke
brain
ct
scan
exclud
intracerebr
haemorrhag
women
nonchildbear
potenti
ie
physiolog
incap
becom
pregnant
includ
woman
postmenopaus
childbear
potenti
neg
urin
pregnanc
test
immedi
randomis
vascular
imag
done
randomis
show
moder
greater
stenosi
intern
carotid
vertebrobasilar
middl
cerebr
anterior
cerebr
posterior
cerebr
arteri
confi
rmed
carotid
duplex
scan
transcrani
doppler
imag
magnet
reson
angiographi
accord
previous
publish
criteria
randomis
patient
except
two
inelig
two
withdrew
consent
receiv
alloc
treatment
complet
studi
month
neuroimag
done
randomis
result
neuroimag
interpret
without
knowledg
treatment
alloc
patient
laod
confi
rmed
neuroimag
includ
primari
analysi
exclus
criteria
follow
prestrok
modifi
ed
rankin
scale
mr
score
greater
nation
institut
health
stroke
scale
nihss
score
greater
histori
intracerebr
haemorrhag
known
contraind
use
lmwh
aspirin
includ
haemorrhag
diathesi
patient
anticoagul
therapi
exclud
aspirin
onset
stroke
defi
nite
indic
anticoagul
sustain
hypertens
blood
pressur
mm
hg
immedi
randomis
coexist
system
diseas
termin
carcinoma
renal
failur
creatinin
known
cirrhosi
sever
dementia
psychosi
brain
tumour
signifi
cant
nonischaem
brain
lesion
brain
ct
scan
atrial
fi
brillat
ecg
past
present
chronic
rheumat
heart
diseas
metal
heart
valv
thrombocytopenia
platelet
count
l
known
particip
anoth
clinic
trial
baselin
data
measur
collect
includ
demograph
medic
histori
prestrok
mr
nihss
score
day
earlier
discharg
outcom
assess
nihss
barthel
index
mr
miniment
state
examin
mmse
month
randomis
nihss
barthel
index
mr
mmse
intern
stroke
trial
ist
question
assess
clinician
nurs
without
knowledg
treatment
alloc
haemorrhag
thromboembol
event
advers
event
overal
mortal
treatment
followup
document
primari
outcom
combin
endpoint
month
defi
ned
surviv
barthel
index
least
good
outcom
use
fissbi
studi
secondari
outcom
includ
nihss
score
day
month
chang
nihss
score
baselin
day
baselin
month
mr
score
day
month
favour
outcom
defi
ned
surviv
mr
score
also
mmse
score
day
month
ist
question
month
good
outcom
independ
defi
ned
ist
outcom
indiff
erent
good
bad
outcom
dependentdead
defi
ned
ist
outcom
dead
bad
overal
mortal
day
month
thromboembol
event
studi
period
recurr
stroke
coronari
syndrom
deep
vein
thrombosi
pulmonari
embolu
ct
scan
brain
randomis
day
read
independ
radiologist
unawar
treatment
alloc
safeti
measur
includ
haemorrhag
episod
occur
day
defi
ned
presenc
follow
symptomat
haemorrhag
transform
cerebr
infarct
symptomat
intracerebr
haemorrhag
associ
cerebr
infarct
asymptomat
haemorrhag
transform
cerebr
infarct
asymptomat
intracerebr
haemorrhag
associ
cerebr
infarct
seriou
extracrani
haemorrhag
eg
gastrointestin
bleed
haematoma
haematuria
thromboembol
event
studi
period
recurr
stroke
coronari
syndrom
deep
vein
thrombosi
pulmonari
embolu
death
caus
death
relat
haemorrhag
complic
neurolog
event
assess
event
evalu
committe
progress
stroke
defi
ned
neurolog
deterior
day
day
onset
symptom
exclud
haemorrhag
transform
infarct
infarct
anoth
vascular
territori
recurr
stroke
defi
ned
neurolog
deterior
day
month
infarct
anoth
vascular
territori
randomis
trial
done
central
randomis
offi
ce
clinic
trial
epidemiolog
research
unit
singapor
mean
seal
envelop
alloc
via
internet
block
randomis
use
block
size
stratifi
ed
region
hong
kong
kowloon
new
territori
singapor
time
onset
stroke
h
h
nihss
score
whether
neurovascular
investig
done
randomis
vascular
lesion
present
vascular
lesion
statu
unknown
onetoon
treatment
alloc
treatment
assign
gener
comput
data
manag
statist
analysi
done
clinic
trial
epidemiolog
research
unit
singapor
independ
investig
toast
studi
placebo
group
treatment
group
laod
subgroup
good
outcom
purpos
sampl
size
calcul
assum
outcom
patient
would
toast
studi
twosid
test
size
power
requir
sampl
size
plan
trial
least
patient
laod
analys
done
intentiontotreat
basi
month
effi
caci
outcom
obtain
last
avail
outcom
use
place
last
observ
carri
forward
method
associ
treatment
group
primari
endpoint
combin
outcom
determin
use
chisquar
test
odd
ratio
or
ci
calcul
twosampl
test
use
assess
quantit
secondari
endpoint
mean
diff
erenc
treatment
group
present
ci
logist
regress
multipl
regress
analys
done
binari
continu
outcom
respect
adjust
stratifi
cation
variabl
time
onset
stroke
h
h
nihss
score
whether
neurovascular
investig
done
randomis
vascular
lesion
present
vascular
lesion
statu
unknown
addit
primari
analysi
laod
subgroup
similar
analys
also
done
randomis
treat
patient
nonlaod
subgroup
trial
data
collect
print
form
subsequ
enter
comput
use
clintrial
softwar
clinsoft
corpor
releas
lexington
usa
statist
analys
gener
use
sa
version
sa
institut
inc
cari
nc
usa
report
studi
done
accord
consort
statement
purpos
report
valu
or
greater
posit
valu
risk
reduct
indic
advantag
lmwh
aspirin
fund
sourc
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
fi
nal
respons
decis
submit
public
enrol
patient
particip
hospit
april
septemb
hospit
screen
log
avail
estim
acut
stroke
patient
elig
per
studi
protocol
common
barrier
recruit
includ
late
present
refus
sever
acut
respiratori
syndrom
epidem
four
patient
receiv
trial
medic
thu
data
record
two
withdrew
consent
two
inelig
due
presenc
exclus
criteria
fi
gure
patient
randomis
lwmh
aspirin
exclud
primari
analysi
accord
protocol
vascular
imag
investig
show
laod
vascular
imag
done
randomis
patient
vascular
imag
done
randomis
vascular
imag
could
done
primari
studi
popul
compris
patient
confi
rmed
laod
patient
vascular
imag
done
randomis
patient
vascular
imag
done
randomis
locat
laod
sole
intracrani
patient
sole
extracrani
intracrani
extracrani
patient
underw
transcrani
doppler
examin
underw
carotid
duplex
doppler
examin
less
underw
magnet
reson
angiographi
baselin
clinic
stroke
characterist
patient
baselin
variabl
two
group
similar
tabl
although
slightli
patient
diabet
mellitu
aspirin
group
primari
outcom
analysi
month
proport
patient
good
outcom
barthel
index
patient
primari
outcom
remain
unalt
adjust
stratifi
cation
variabl
time
onset
stroke
nihss
score
baselin
whether
neurovascular
investig
done
randomis
tabl
adjust
patient
lmwh
still
signifi
cant
advantag
mr
score
adjust
ci
mmse
score
patient
alloc
lmwh
becam
signifi
cantli
higher
compar
alloc
aspirin
adjust
estim
diff
erenc
howev
adjust
analysi
account
stratifi
cation
factor
littl
eff
ect
or
estim
remain
secondari
outcom
signifi
cant
diff
erenc
occurr
haemorrhag
transform
infarct
symptomat
asymptomat
advers
event
seriou
advers
event
haemorrhag
nonhaemorrhag
two
group
tabl
posthoc
analysi
patient
exclud
absenc
laod
proport
patient
good
outcom
month
barthel
index
least
lmwh
group
aspirin
group
arr
ci
effi
caci
outcom
term
independ
patient
shown
fi
gure
secondari
outcom
show
signifi
cant
risk
lmwh
versu
aspirin
outcom
mr
score
versu
lmwh
vs
aspirin
arr
mr
versu
lmwh
vs
aspirin
arr
ist
outcom
lmwh
vs
aspirin
arr
mean
mmse
score
sd
lmwh
versu
sd
aspirin
mean
nihss
score
sd
lmwh
sd
aspirin
adjust
or
estim
primari
secondari
outcom
remain
unchang
signifi
cant
diff
erenc
safeti
measur
two
group
found
tabl
posthoc
analysi
randomis
treat
patient
proport
patient
good
outcom
month
barthel
index
least
lmwh
group
aspirin
group
arr
ci
effi
caci
outcom
term
patient
independ
shown
fi
gure
secondari
outcom
show
signifi
cant
benefi
lmwh
aspirin
outcom
mr
score
versu
lmwh
vs
aspirin
arr
mr
score
versu
lmwh
vs
aspirin
arr
ist
outcom
lmwh
vs
aspirin
arr
mean
mmse
score
sd
lmwh
sd
aspirin
mean
nihss
score
sd
lmwh
sd
trial
design
assess
eff
ect
lmwh
versu
aspirin
acut
stroke
patient
laod
predominantli
due
intracrani
atherosclerosi
ischaem
stroke
heterogen
diseas
three
main
stroke
subtyp
cardioembol
laod
small
vessel
diseas
divers
stroke
mechan
best
acut
treatment
individu
stroke
subtyp
may
diff
erent
previou
acut
trial
anticoagul
systemat
target
underli
arteri
lesion
patient
laod
atherothrombosi
common
mechan
thu
anticoagul
may
particularli
use
stroke
subtyp
previou
posthoc
analysi
suggest
anticoagul
may
benefi
cial
among
patient
intern
carotid
occlus
diseas
among
acut
stroke
patient
intracrani
atherosclerosi
microemboli
detect
patient
use
transcrani
doppler
monitor
patient
multipl
acut
infarct
diff
usionweight
mri
suggest
arterytoarteri
embol
import
stroke
mechan
patient
middl
cerebr
arteri
stenosi
although
data
show
defi
nitiv
benefi
lmwh
aspirin
result
compat
earlier
studi
asian
patient
high
risk
intracrani
atherosclerosi
moreov
result
also
suggest
lmwh
might
hazard
patient
without
laod
futur
larg
studi
anticoagul
acut
stroke
patient
laod
done
clarifi
role
anticoagul
diff
erent
stroke
subtyp
choic
primari
outcom
measur
crucial
case
acut
stroke
barthel
index
use
studi
commonli
use
disabl
measur
acut
stroke
trial
howev
barthel
index
sensit
measur
among
patient
rel
mild
stroke
stroke
sever
patient
rel
mild
median
barthel
index
score
patient
score
least
month
sever
recent
studi
use
dichotomis
mr
score
combin
sever
outcom
measur
global
statist
test
choic
primari
outcom
measur
may
determin
whether
trial
posit
neg
futur
studi
patient
intracrani
atherosclerosi
may
consid
use
dichotomis
mr
score
primari
outcom
measur
found
lmwh
group
slightli
better
cognit
function
term
mmse
score
cognit
function
play
vital
role
independ
live
patient
without
physic
impair
cognit
impair
may
need
help
daili
function
diff
erenc
cognit
outcom
might
explain
diff
erenc
disabl
statu
although
diff
erenc
nihss
score
measur
physic
impair
howev
diff
erenc
could
also
indic
small
diff
erenc
baselin
mmse
group
data
suggest
futur
acut
stroke
trial
measur
cognit
function
outcom
indic
academ
fund
studi
done
without
substanti
support
industri
moreov
data
analys
done
independ
investig
use
predominantli
ultrasound
delin
vascular
lesion
also
strengthen
methodolog
studi
howev
use
openlabel
trial
medic
might
caus
bia
even
though
assessor
month
unawar
treatment
alloc
use
last
observ
carri
forward
method
could
introduc
substanti
bia
addit
rel
small
sampl
size
could
provid
mislead
conclus
possibl
benefi
hazard
howev
eff
ect
would
small
analysi
miss
data
studi
nevertheless
result
studi
resurrect
interest
larg
clinic
trial
anticoagul
acut
ischaem
stroke
patient
laod
especi
intracrani
diseas
k
wong
c
chen
p
w
ng
h
tsoi
h
l
li
w
c
fong
j
yeung
c
k
wong
k
k
yip
particip
design
protocol
recruit
patient
wrote
draft
manuscript
h
gao
h
b
wong
collect
case
record
form
statist
analysi
wrote
statist
result
manuscript
author
approv
fi
nal
version
manuscript
confl
ict
interest
